🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are on the rise around the world, with estimates suggesting over 82 million new cases each year. Notably increased rates are reported in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

One new antibiotic, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The research involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in many developing nations.

Medical professionals directly involved have voiced positive views. Having a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.